Table 2

Eligible study protocols

Identifier	Country	Study design	Arms	Intervention	Comparison	Sample size	Follow-up period
NCT04357730	USA	RCT	2 arms	Alteplase	Standard of care	50	28 days
NCT04640194	Austria, Belgium, Brazil, Denmark France, Germany, Italy, Netherlands, Portugal, Russian Federation, Spain	RCT	3 arms	Alteplase (low dose) on top of standard of care Alteplase (high dose) on top of standard of care	Standard of care	320	28 days
NCT04505592	USA	RCT	2 arms	Tenecteplase	Placebo	60	28 days
IRCT20200415047080N1	Iran	RCT	2 arms	Alteplase	Standard of care	30	28 days
IRCT20200515047456N1	Iran	RCT	3 arms	rtPA	Standard of care	15	30 days

RCT, randomised controlled trial; rtPA, recombinant tissue plasminogen activator.